Diagnostic Challenges in the Treatment of Sjogren Syndrome

Abstract

Sjogren's syndrome (SS), an autoimmune disease that mostly affects the exocrine glands, results in dryness of the mucosal surfaces, especially the oral and ocular ones. The clinical appearance may range from simple symptoms such as mucosal dryness, arthralgias, and moderate purpura to significant systemic manifestations; it is often linked to cancer, especially non-Hodgkin lymphoma. Histologically, SS is characterized by tissue damage due to lymphocyte infiltration. While the exact pathogenetic pathways are unknown, cellular B hyperactivity with auto-antibody synthesis is a significant factor. The primary immunological markers are La/SSB (the most specific), anti-Ro/SSA, and anti-nuclear antibodies (the most commonly identified). Recognizing cryoglobulinemia, hypergammaglobulinemia, hypocomplementemia, and rheumatoid factor positive as prognostic indicators is also crucial since it may assist determine who should receive more intensive therapy. In fact, the goal of this study is to concentrate on the practical elements of managing SS patients, with an emphasis on diagnosis and treatment. When it comes to diagnosis, it is crucial to stress that while a number of classification criteria have been established over time, they are not diagnostic criteria. Instead, the clinician makes the diagnosis, perhaps with the help of instrumental investigations such as magnetic resonance imaging of parotids, high-frequency ultrasound (which is helpful as an assisting tool in labial biopsy), and ultrasound. In order to determine where to apply earlier and more aggressive therapies, treatments (from symptomatic ones to new biological therapies) should instead be tailored to the severity and organ commitment of the disease, monitoring serologic changes, and stratifying patients for the risk of developing NHL.